CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤患者药物研发现状：中国与全球对比综述
英文原题：Current status of drug development for patients with multiple myeloma: a review of comparison in China and the rest of world.
查看英文原题
Current status of drug development for patients with multiple myeloma: a review of comparison in China and the rest of world.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多发性骨髓瘤（MM）是一种高度异质性的恶性肿瘤。近年来，MM的治疗取得了显著进展。靶向B细胞成熟抗原（BCMA）的免疫治疗和CAR-T（CAR-T）细胞疗法已获批用于治疗复发/难治性MM（RRMM），并将很快在中国上市。CD38（分化簇38）抗体daratumumab改善了RRMM和新诊断MM患者的临床结局。daratumumab、bortezomib和dexamethasone的联合方案在中国作为一线治疗取得了良好的疗效。然而，高危患者从这些先进疗法中获益有限，通常早期复发，进展为侵袭性终末期MM。因此，需要寻求新型疗法以改善这些患者的肿瘤预后。本综述概述了这些新型药物的近期临床进展，并将中国正在开发的候选药物与全球其他地区进行了比较。
展开英文摘要原文
Multiple myeloma (MM) is a highly heterogeneous malignancy. The treatment of MM has been significantly advanced in recent years. B cell maturation antigen (BCMA)-targeted immunotherapy and chimeric antigen receptor T (CAR-T) cell therapy have been approved for the treatment of relapsed and refractory MM (RRMM), which will be launched in China shortly.
The CD38 (cluster of differentiation 38) antibody, daratumumab, improves the clinical outcomes both RRMM and newly diagnosed MM patients. The combination of daratumumab, bortezomib and dexamethasone achieved favorable outcomes as the first-line therapy in China.
However, high-risk patients have limited benefits from these advanced therapeutics, and usually relapse early, progressing into aggressive end-stage MM.
Therefore, novel therapies are sought to improve the cancer prognosis in these patients. This review furnishes an overview of the recent clinical developments of these novel drugs and compares the drug candidates under development in China to the rest of the world.
论文信息
- 作者
- Huang L、Zhang J、Punnoose E、Xiao Z、Li W
- 单位
- Oncology Biomarker Development, Roche (China) Holding Ltd., Shanghai 201203, China.China
- 文献类型
- 综述
- 期刊
- Antibody therapeutics2023 Apr
- 原文标识
- PubMed 37324548 · DOI 10.1093/abt/tbad010